IngredientsMicrotea debilis Sw. is the accepted scientific name for the plant commonly known in English as weak jumby pepper. The genus Microtea — collectively called "jumby peppers" — comprises flowering plants in the family Microteaceae, native to the Caribbean islands, Central America, and tropical South America. The species epithet debilis (Latin for "weak" or "feeble") reflects the plant's delicate, procumbent growth habit. The genus Microtea was originally placed in the family Phytolaccaceae, but is now placed in its own family, the Microteaceae.
First published in Prodromus Vegetabilium Indiae Occidentalis (1788) by Olof Swartz, the species is accepted as native to Tropical America and is an annual that grows primarily in the seasonally dry tropical biome. The taxon was described and re-described by multiple authors over the 19th century, resulting in several synonyms. Recognized synonyms include Schollera debilis (Sw.) Rohr (1792), Microtea debilis var. ovata Delile ex Moq. and Microtea debilis var. rhombifolia Moq., both published in A.P. de Candolle's Prodromus (1849).
Within the genus, Microtea is divided into two major sister clades: clade A consisting of M. glochidiata, M. maypurensis, and M. tenuifolia, and clade B comprising M. debilis, M. sulcicaulis, M. scabrida, M. celosioides, and M. papillosa. The basal position of the small American genus Microtea within the core Caryophyllales was suggested only recently in accordance with molecular phylogeny, and the specific relationships within the genus were not fully traced until phylogenetic analysis based on the matK chloroplast gene confirmed the monophyly of Microtea.
The plant is known as Demoiselle in French, Herbe-au-long-case in the Lesser Antilles, and "Weak Jumby Pepper" in English. The U.S. Fish & Wildlife Service lists the official common name as weak jumby pepper.
The species is an annual, glabrous herb with decumbent stems up to 30 cm; the rosulate leaves grow up to 8.0 cm and are long-petiolate (petioles up to 3.0 cm), obovate or oblong, and mostly persistent at fruiting; cauline leaves are rhombic or ovate, cuneate; the inflorescence is a one-sided spike with sessile or very shortly pedicellate flowers; bracteoles are mostly absent or tiny; perianth segments 4–5, greenish, lanceolate or oblong; stamens 4–5; stigmas 2, thick; fruits are almost orbicular or broadly ovate, 0.9–1.1 × 0.9–1.0 mm, reticulate, without any projections. The family Microteaceae comprises a single genus with several annual species distributed in the tropical parts of America, distinguished by its possession of small (1–3 mm), spherical, and indehiscent fruits containing a single seed.
The documented native range spans Belize, Bolivia, Brazil North, Brazil Northeast, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, French Guiana, Guatemala, Guyana, Haiti, Honduras, Jamaica, the Leeward Islands, Nicaragua, Panamá, Paraguay, Peru, Puerto Rico, the Southwest Caribbean, Suriname, Trinidad-Tobago, Venezuela, and the Windward Islands. The species has also been recorded from Brazil South and Cameroon. The occurrence in Cameroon represents a disjunct introduction outside the native range of the Americas.
The most thoroughly documented traditional use of Microtea debilis comes from Suriname, in northeastern South America. The use of this plant against "proteinuria" in traditional medicine in Suriname (South America) is the primary recorded folk application. This use — targeting elevated protein in the urine — reflects a renal or urinary tract indication that was systematically investigated by researchers in the late 20th century (see Section 4.1 below).
Ligand-binding studies on twelve different receptors were used for screening extracts from plants collected in Suriname, and the results on 5-HT1A, A1, and NMDA receptors promoted further investigation of Microtea debilis. This receptor-based ethnopharmacological screening was the direct outcome of surveys of traditional medicinal plant use in Suriname, placing the plant within the documented inventory of folk medicines of that country.
The native range of the species is Tropical America, it grows primarily in the seasonally dry tropical biome, and it is used as a medicine. The Caribbean region has a long history of using herbal medicine for disease management and maintenance of health. Plants are utilized extensively throughout the Caribbean in the practice of folklore botanical medicine, which originated from the intense cultural convergence prompted by European colonialism, indigenous cultures of the Americas, the transatlantic slave trade, and immigration of indentured servants from Asia.
The common name Herbe-au-long-case used in the Lesser Antilles suggests the plant has a documented popular identity in Francophone Caribbean territories. The French vernacular name Demoiselle is recorded across several Francophone territories. However, beyond the Surinamese use for proteinuria and the general ethnobotanical recognition of the plant as medicinal, no detailed documentation of its preparation methods, dosing conventions, or other specific therapeutic applications from traditional Caribbean or Latin American communities has been retrieved from peer-reviewed sources in this search. The plant is listed in the TRAMIL network's broader inventory of Caribbean medicinal plants, and regional ethnobotanical programs such as TRAMIL have catalogued plants from the Lesser Antilles region. TRAMIL is a program of applied research focusing on popular medicine, initiated in 1982 to understand, validate, and expand primary health care practices based on the use of medicinal plants in the Caribbean.
No peer-reviewed sources retrieved in this research specify the exact traditional preparation method for Microtea debilis as used in Suriname. The phytochemical and pharmacological studies (see Sections 3 and 4) employed crude plant extracts prepared from dried aerial parts using aqueous or hydroalcoholic solvents, which is broadly consistent with how decoctions and infusions are prepared in traditional Caribbean and Surinamese herbal medicine. The whole, dried plant comes from South America; it is ground to obtain a powder, and extraction from the ground plant is performed in a mixture of 96.2% ethanol and Hâ‚‚O (80/20, v/v) at room temperature. This extraction methodology was employed in cosmetic/patent contexts and reflects a standardized laboratory approach rather than a documented traditional preparation.
The major bioactive compounds documented in Microtea debilis are flavonoids, specifically polymethoxylated flavones and their glycosides. Two new 5-O-glucosylflavones — 5-O-β-D-glucopyranosyl cirsimaritin (compound 1) and 5,4′-O-β-D-diglucopyranosyl cirsimaritin (compound 2) — four known flavonoids: cirsimarin (compound 3), cirsimaritin (compound 4), salvigenin (compound 5), 4′,5-dihydroxy-7-methoxyflavone (compound 6), and a norisoprenoid vomifoliol (compound 7), have been isolated from the aerial parts of Microtea debilis.
The identity and classification of the principal compounds are as follows:
Cirsimaritin has also been identified and isolated from other medicinal plants including Artemisia judaica, Cirsium japonicum, Lithocarpus dealbatus, and Ocimum sanctum, confirming the compound's occurrence across the plant kingdom.
The two novel glucosylflavones isolated from M. debilis represent unique structures not previously described in other species at the time of their isolation. The two new 5-O-glucosylflavones (compounds 1 and 2) are cirsimaritin derivatives bearing one or two glucopyranose units at the 5- and 4′-positions respectively. These novel glycosides extend the known phytochemical diversity of the species beyond the previously characterized cirsimarin and its aglycone.
All species within the genus Microtea share similar pericarp and seed ultrasculpture and anatomy, and they share the reticulate pericarp surface and rugose or slightly alveolate seed ultrasculpture. However, the chemical constituents specifically characterized to date have been derived from the aerial (above-ground) parts of the plant, and no systematic phytochemical profiling of roots, seeds, or fruit separately has been recovered in peer-reviewed sources for this species.
The most rigorously established mechanism of action for compounds derived from Microtea debilis involves antagonism at adenosine receptors, principally the A1 and A2 receptor subtypes.
In ligand-binding studies, extracts of Microtea debilis have been shown to inhibit the binding of [³H]1,3-dipropyl-8-cyclopentylxanthine ([³H]DPCPX) to adenosine-A1 receptors in rat forebrain membranes; subsequently, cirsimarin was isolated as the active component and shown to function as an adenosine antagonist at the adenosine-A1 receptor in vitro.
In further investigations, adenosine-A2 receptor activity was studied; cirsimarin inhibited the binding of [³H]5′-N-ethylcarboxamidoadenosine ([³H]NECA) to adenosine-A2 receptors in rat striatum with an inhibition constant, Ki, of 6.5 ± 0.3 mM.
Adenosine A1 receptors are expressed in numerous tissues, including the kidney and adipose tissue. Blockade of A1 receptors in renal tubular cells has been proposed to reduce tubular reabsorption of proteins, offering a mechanistic rationale for the traditional anti-proteinuric use. The antagonistic properties of cirsimarin at A1 receptors explain its effect on proteinuria through interaction with A1 receptors present on the surface of renal cells.
Compound 6 (4′,5-dihydroxy-7-methoxyflavone) was found to be a potent inhibitor of nitrite production in macrophages in LPS-stimulated RAW264.7 macrophage cell assays. Nitric oxide (NO), measured indirectly as nitrite, is a key mediator of inflammatory signalling. Inhibition of its overproduction in activated macrophages is a recognized mechanism of anti-inflammatory activity for flavonoids.
Biological effect investigations carried out with cirsimaritin across a wide variety of experimental models showed biological properties including anticancer, antimicrobial, antidiabetic, antiparasitic, and antioxidant effects; cirsimaritin induces anti-inflammatory and antiproliferative effects by inhibiting cell membrane receptors, interference with signaling pathways, and inhibiting transcriptional factors such as NF-κB involved in cell promotion and proliferation.
Cirsimarin extracted from Microtea debilis Swartz was assessed for its ability to trigger lipid mobilization; its lipolytic activity was tested on isolated adipocytes from rats and compared to caffeine, a well-known lipolytic agent; results show an EC₅₀ = 0.025 ± 0.01 mM for cirsimarin versus 0.49 ± 0.08 mM for caffeine; cirsimarin also inhibits phosphodiesterase, the enzyme that modulates cyclic nucleotide signalling; the results demonstrate that cirsimarin exerts strong lipolytic properties, being approximately 20 times more potent than caffeine to stimulate lipolysis, at least in part through cyclic nucleotide preservation.
Cirsimarin's probable mechanism of action for lipolysis corresponds to blockage of the A1 receptors present on the surface of adipocytes. This dual mechanism — phosphodiesterase inhibition and A1 receptor antagonism on adipocytes — may together explain the observed lipolytic potency.
Traditional basis: In traditional medicine, Microtea debilis is used against proteinuria.
Preclinical evidence (in vitro / animal): In ligand-binding studies, extracts of Microtea debilis inhibited the binding of [³H]DPCPX to adenosine-A1 receptors in rat forebrain membranes; cirsimarin was subsequently isolated as the active component and shown to function as an adenosine antagonist at the adenosine-A1 receptor in vitro. In the rat in vivo model, the concentrations of cirsimaritin in plasma were 0.126 ± 0.04, 0.138 ± 0.015, and 0.120 ± 0.022 μM at 2, 5, and 12 hours respectively after administration of 8 mg/kg cirsimarin; concentrations in urine were substantially higher at the same time points. The inhibition of [³H]DPCPX binding at the adenosine-A1 receptor by urine samples collected 2, 5, and 12 hours after oral administration of 8 mg/kg cirsimarin or a crude extract of M. debilis containing approximately 8 mg/kg cirsimarin was not significantly different from that of urine from untreated rats, in contrast with urine collected 1–2 days after oral administration of 80 mg/kg cirsimarin; approximately 3% of cirsimarin was excreted in urine as cirsimaritin.
The results indicate that in the kidney and urinary tract the concentrations of cirsimaritin produced after ingestion of more than 8 mg/kg cirsimarin can be high enough to inhibit the interaction of adenosine with its receptors; this might explain the effectiveness of Microtea debilis preparations against proteinuria in traditional medicine.
Evidence strength: The evidence is limited to in vitro receptor-binding assays and rat in vivo pharmacokinetic/pharmacodynamic studies. There are no published human clinical trials examining Microtea debilis preparations or isolated cirsimarin for the treatment of proteinuria or any other renal indication. The mechanism is scientifically plausible but remains at the preclinical stage.
In vitro evidence: All isolates were tested for cytotoxicity in human cancer cell lines (HepG2, COLO 205, and HL-60) and anti-inflammatory activities in LPS-treated RAW264.7 macrophages; compound 6 (4′,5-dihydroxy-7-methoxyflavone) was found to be a potent inhibitor of nitrite production in macrophages; compounds 2, 4, 6, and 7 showed moderate anti-proliferative activity against COLO-205 cells with IC₅₀ values of 7.1, 13.1, 6.1, and 6.8 μM, respectively.
Evidence strength: Strictly in vitro. No animal model anti-inflammatory studies or human trials have been published for Microtea debilis as a whole or for its specific flavonoid constituents in the context of inflammatory disease. The individual constituent cirsimaritin has been reviewed across multiple plant sources, and the results of research into cirsimaritin showed biological properties including anticancer, antimicrobial, antidiabetic, antiparasitic, and antioxidant effects; cirsimaritin appears as a promising and viable alternative natural bioactive drug to treat many pathological conditions. However, this conclusion derives from a review of cirsimaritin as a compound class, not specifically from clinical trials of M. debilis.
In vitro evidence: Antiproliferative activity has been evaluated in established human cancer cell lines. Two new glucosylflavones and four known flavonoids and one norisoprenoid were isolated from aerial parts of Microtea debilis and tested for cytotoxicity in human cancer cell lines (HepG2, COLO 205, and HL-60) and anti-inflammatory activities; compound 6 was found to be a potent inhibitor of nitrite production in macrophages; compounds 2, 4, 6, and 7 showed moderate anti-proliferative activity against COLO-205 cells with IC₅₀ values of 7.1, 13.1, 6.1, and 6.8 μM, respectively.
HepG2 (hepatocellular carcinoma), COLO 205 (colorectal adenocarcinoma), and HL-60 (promyelocytic leukemia) are commonly used standard cell lines in initial cytotoxicity screening. IC₅₀ values in the low micromolar range (6–13 μM) for several compounds against COLO-205 indicate moderate antiproliferative potency in vitro. Importantly, no anti-proliferative activity at these concentrations was reported for HepG2 or HL-60 in the published abstract, suggesting selectivity may vary by cell line and compound.
Evidence strength: Preliminary in vitro only. No animal tumor models or human oncology trials exist in the published peer-reviewed literature for this species.
Preclinical and in vitro evidence: Cirsimarin extracted from Microtea debilis exerts in vitro a strong lipolytic activity on isolated adipocytes. Its lipolytic activity was assessed on isolated adipocytes from rats and compared to caffeine; results show an EC₅₀ = 0.025 ± 0.01 mM for cirsimarin versus 0.49 ± 0.08 mM for caffeine. A subsequent animal study investigated whether this translates to reduced fat deposition in vivo: a study reported that the flavonoid cirsimarin decreases fat deposition in mice intra-abdominal adipose tissue.
This body of evidence prompted patent filings in France (FR2849775A1, Gattefossé SAS) covering the use of cirsimarin or cirsimaritin in cosmetic compositions for the topical treatment of cellulite. The invention relates to the use of cirsimarin or derivatives for producing a composition used to activate lipolysis; it relates to a cosmetic composition based on cirsimarin or cirsimarin derivatives, intended in particular for the cosmetic treatment of cellulite.
Evidence strength: Preclinical (in vitro isolated adipocytes, mouse model). No human clinical trial data are available for cirsimarin's efficacy in reducing adipose tissue or treating cellulite when derived from Microtea debilis. This evidence base, while mechanistically promising, remains at the discovery/preclinical stage.
Ligand-binding studies on twelve different receptors using extracts from Surinamese plants showed that results on 5-HT1A, A1, and NMDA receptors promoted further investigation of Microtea debilis. This indicates that crude extracts of the plant demonstrated activity not only at adenosine A1 receptors, but also at serotonin 5-HT1A receptors and NMDA (N-methyl-D-aspartate) glutamate receptors in initial screening assays. The identity of the constituent(s) responsible for the 5-HT1A and NMDA receptor activities has not been resolved in published peer-reviewed literature based on available sources. No further mechanistic or in vivo neurological studies for M. debilis have been identified.
Evidence strength: Preliminary screening data only. No mechanistic follow-up studies or in vivo/clinical evidence for neurological applications exist in the accessible literature.
No standardized human dosage forms or clinical doses have been established for Microtea debilis as a dietary supplement or botanical medicine. The following dosages are reported exclusively in the context of preclinical pharmacological research and should not be interpreted as clinical recommendations.
No formal toxicological evaluation — including LD₅₀, NOAEL, chronic toxicity studies, or genotoxicity assays — specifically for Microtea debilis whole plant or its standardized extracts has been identified in the accessible peer-reviewed literature. The plant is not listed in WHO monographs, ESCOP monographs, the German Commission E, the European Pharmacopoeia, or databases maintained by the NIH Office of Dietary Supplements. No Cochrane reviews or systematic reviews of its safety have been identified.
The principal documented mechanism of cirsimarin — adenosine A1 and A2 receptor antagonism — is pharmacologically significant. Adenosine receptors modulate cardiac function (A1 receptors mediate negative chronotropic and dromotropic effects), renal tubular function, and central nervous system activity. Compounds that antagonize adenosine receptors could theoretically interact with drugs that depend on adenosine signaling, including adenosine itself (used clinically for supraventricular tachycardia), dipyridamole (which increases endogenous adenosine levels), or methylxanthines (caffeine, theophylline) that share the same receptor targets. Cirsimarin was shown to function as an adenosine antagonist at the adenosine-A1 receptor in vitro. However, the clinical significance of such interactions has not been studied in human subjects.
Approximately 3% of cirsimarin was excreted in urine as cirsimaritin; the results indicate that in the kidney and urinary tract the concentrations of cirsimaritin produced after ingestion of more than 8 mg/kg cirsimarin can be high enough to inhibit the interaction of adenosine with its receptors. This dose-dependence in rats — with meaningful renal adenosine receptor inhibition appearing at higher rather than lower doses — has implications for both therapeutic potential and risk of off-target effects at the renal level.
Cirsimarin exerts strong lipolytic properties, being approximately 20 times more potent than caffeine to stimulate lipolysis in isolated rat adipocytes. The metabolic consequences of potent lipolysis stimulation — including increased circulating free fatty acids — have potential implications for cardiovascular and metabolic health, particularly in individuals with existing dyslipidemia or insulin resistance. These considerations have not been evaluated in human clinical studies.
Microtea debilis is not reviewed in any major pharmacopoeial monograph or regulatory assessment document from the EMA, EFSA, WHO, or NIH identified in this search. It is not listed as a Generally Recognized as Safe (GRAS) substance by the U.S. FDA for use in foods or dietary supplements in available sources. The cosmetic patent applications based on cirsimarin (from Gattefossé SAS, France) represent the most advanced formal regulatory engagement identified, relating to topical cosmetic use rather than oral supplementation.
The genus Microtea was originally placed in the family Phytolaccaceae, but is now placed in its own family, the Microteaceae. Historically, this meant that older pharmacological literature cited the species under the designation "Phytolaccaceae," and papers from the 1990s and 2000s use this former classification (e.g., "cirsimarin and cirsimaritin, flavonoids of Microtea debilis (Phytolaccaceae)"). Researchers and practitioners cross-referencing older literature should be aware of this taxonomic reclassification.
Microtea debilis is a small tropical annual herb with a documented traditional use against proteinuria in Suriname and general recognition as a medicinal plant across the wider Caribbean and tropical American region. Its pharmacological investigation has been driven primarily by bioassay-guided phytochemical fractionation, yielding a set of polymethoxylated flavones — cirsimarin, cirsimaritin, salvigenin, and two novel glucosylflavones — as the principal bioactive compounds. The most rigorously investigated mechanism is adenosine A1 receptor antagonism, which provides a plausible molecular rationale for the traditional renal use. Additional in vitro activities (anti-inflammatory via NO inhibition, antiproliferative in COLO-205 cells, potent lipolysis stimulation) have been demonstrated but remain at early preclinical stages. No human clinical trials for any indication have been published, and no formal safety evaluation, pharmacopoeial monograph, or regulatory classification has been established for Microtea debilis as a dietary supplement or herbal medicine.
Health conditions that Microtea debilis may help support.
Body systems that Microtea debilis may help support.
Go back